Based on the Danaher Corporation stock forecast from 16 analysts, the average analyst target price for Danaher Corporation is USD 271.65 over the next 12 months. Danaher Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Danaher Corporation is Slightly Bearish, which is based on 5 positive signals and 10 negative signals. At the last closing, Danaher Corporation’s stock price was USD 181.77. Danaher Corporation’s stock price has changed by -11.70% over the past week, -15.38% over the past month and -25.59% over the last year.
No recent analyst target price found for Danaher Corporation
No recent average analyst rating found for Danaher Corporation
Company Overview Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia. Read Less
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment off...Read More
Frequently Asked Questions About Danaher Corporation (DHR) Stock
Based on ratings from 16 analysts Danaher Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 20 buy, sell and 6 hold ratings.
DHR stock's dividend yield is 0.60%.
Our analysis grades DHR stock's dividend yield at F. This means that DHR stock's dividend yield is above 17% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a poor dividend stock for its sector.
Based on targets from 16 analysts, the average taret price for DHR is USD 271.65 over the next 12 months. The maximum analyst target price is USD 315 while the minimum anlayst target price is USD 240.
DHR stock's Price/Earning ratio is 40.16.
Our analysis grades DHR stock's Price / Earning ratio at F. This means that DHR stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be fairly valued for its sector
The last closing price of DHR's stock was USD 181.77.
The most recent market capitalization for DHR is USD 151.57B.
Based on targets from 16 analysts, the average taret price for DHR is projected at USD 271.65 over the next 12 months.
This means that DHR's stock price may go up by +49.45% over the next 12 months.
We can't find any ETFs which contains Danaher Corporation's stock.
As per our most recent records Danaher Corporation has 61,000 Employees.
Danaher Corporation's registered address is 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701.
You can get more information about it from Danaher Corporation's website at https://www.danaher.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Danaher Corporation (DHR) Stock
Based on ratings from 16 analysts Danaher Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 20 buy, sell and 6 hold ratings.
DHR stock's dividend yield is 0.60%.
Our analysis grades DHR stock's dividend yield at F. This means that DHR stock's dividend yield is above 17% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a poor dividend stock for its sector.
Based on targets from 16 analysts, the average taret price for DHR is USD 271.65 over the next 12 months. The maximum analyst target price is USD 315 while the minimum anlayst target price is USD 240.
DHR stock's Price/Earning ratio is 40.16.
Our analysis grades DHR stock's Price / Earning ratio at F. This means that DHR stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be fairly valued for its sector
The last closing price of DHR's stock was USD 181.77.
The most recent market capitalization for DHR is USD 151.57B.
Based on targets from 16 analysts, the average taret price for DHR is projected at USD 271.65 over the next 12 months.
This means that DHR's stock price may go up by +49.45% over the next 12 months.
We can't find any ETFs which contains Danaher Corporation's stock.
As per our most recent records Danaher Corporation has 61,000 Employees.
Danaher Corporation's registered address is 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701.
You can get more information about it from Danaher Corporation's website at https://www.danaher.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DHR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
